Linear *E*- and *Z*-trisubstituted alkenes occur widely in nature and are used regularly in preparative chemistry^[@R1],[@R2]^ (for example, in catalytic enantioselective hydrogenations^[@R3]^, allylic substitutions^[@R4]^, or conjugate additions^[@R5]^). Several approaches have been developed for generating acyclic trisubstituted alkenes, but these have key shortcomings. Unless an α-alkoxy ketone is involved^[@R6]^, Wittig-type transformations are minimally stereoselective^[@R7],[@R8]^. Protocols for converting alkynes or carbonyl-containing compounds to trisubstituted alkenes entail lengthy sequences^[@R9],[@R10],[@R11]^, strongly acidic or basic conditions^[@R10],[@R11],[@R12],[@R13]^, and/or just one stereoisomer^[@R12],[@R14]^ can be accessed (see the [Supplementary Information, Section 1](#SD1){ref-type="supplementary-material"}, for extended bibliography). The higher energy *Z* isomers can be obtained only if there is a suitable directing group^[@R15],[@R16]^. There are no catalytic, high yielding, broadly applicable, and stereoselective methods for formation of trisubstituted alkenes, particularly in either stereoisomeric form. Especially desirable would be strategies that provide access to *E*- as well as *Z*-trisubstituted alkenyl chlorides and bromides, which are found in biologically active natural products^[@R17]^, and may be used to access countless other alkenes through cross-coupling.

The main challenges {#S1}
===================

There are only a small number of reports on synthesis of trisubstituted alkenes by cross-metathesis^[@R18],[@R19],[@R20],[@R21]^. In just two cases stereoisomerism is a concern^[@R18],[@R20]^, and, in each instance, reactions are either minimally selective or afford the *E* isomer preferentially because stereoselectivity results from substrate control.

Designing methods for kinetically controlled *E*- or *Z*-selective^[@R22],[@R23]^ synthesis of trisubstituted alkenes is difficult^[@R24]^ for several reasons. The metallacyclobutane intermediates are relatively hindered, and there is a smaller energy differences between the *E* and *Z* isomers^[@R25]^ (compared to 1,2-disubstituted alkenes). There is also an inherent lack of chemoselectivity: in cross-metathesis, when a trisubstituted alkene is desired, typically one starting material is a monosubstituted and the other a 1,1-disubstituted alkene, both containing an unsubstituted terminal alkenyl methylene unit. Consequently, ethylene can be generated as the byproduct of cross-metathesis or due to homo-metathesis of the less hindered/more reactive reaction partner. Ethylene formation leads to an unstable methylidene complex^[@R26]^, causing low turnover numbers and/or frequencies. It was therefore not surprising that reaction of 1,1-disubstituted alkene **1a** with *Z*-1,2-dichloroethene (*Z*-**2**; [Fig. 1a](#F1){ref-type="fig"}) needed 10 mol% **Mo-1** or **Mo-2** along with 12 hours to furnish **3a** in 81% and 65% yield with moderate stereoselectivity (80:20 and 70:30 *E:Z*, respectively); control experiments indicated minimal post-metathesis isomerization. The transformation involving 4-*tert*-butyl-α-methyl styrene was less efficient (**3b**, 30% yield) but more stereoselective, owing to better substrate control.

The above transformations begin with monosubstituted alkene **4** being generated exclusively ([Fig. 1b](#F1){ref-type="fig"}), revealing that initiation entails reaction of Mo complex **i** with **1a** (not *Z*-**2**) to give disubstituted alkylidene **ii**. Reaction of **ii** with *Z*-**2** may subsequently lead to the putative chloro-substituted alkylidene **iii**^[@R27]^, which may then react with **1a** to give methylidene **v** and **3a** via metallacyclobutane **iv**, with the quaternary carbon center at the less hindered Cβ^[@R28]^ (for more detailed analysis, see [Extended Data Fig. 1](#F6){ref-type="fig"}). Hence, despite the absence of a terminal alkene, sufficient ethylene is generated so that the short lifetime of methylidene species **v** translate to the need for high catalyst loadings and extended reaction times. High *E* selectivity is possible only when one Cβ substituent in **iv** is much larger.

More highly substituted alkenes as substrates {#S2}
=============================================

Use of a trisubstituted alkene, such as *E*-**6** ([Fig. 1c](#F1){ref-type="fig"}) could improve efficiency and stereoselectivity ([Fig. 1c](#F1){ref-type="fig"}). Complex **i** would react first with *Z*-1,2-dichloroethene (*Z*-**2** vs. *E*-**6**) to afford chloro-alkylidene **iii**; indeed, treatment of a mixture of *Z*-**2** and *E*-**6** with **Mo-1** or **Mo-2** generated chloro-alkene **5** exclusively (based on ^1^H NMR analysis). Reaction via metallacyclobutane **vii** would be more stereoselective compared to the less substituted **iv**, because the competing addition mode would yield a less stable metallacyclobutane with the Cα methyl group oriented towards the larger aryloxide ligand. Another advantage would be the intermediacy of ethylidene **vi**, as opposed to methylidene (**v**), leading to longer catalyst lifetime and improved efficiency. If successful, a solution would come to light based on the counterintuitive principle that efficiency and stereoselectivity can be improved by using a more hindered substrate.

The possibility of a trisubstituted alkene substrate poses new challenges. One is the need to promote efficient reactions of more highly substituted alkenes, and if trisubstituted alkenes are difficult to obtain, why consider using them as starting materials? The answer to the latter question is that some trisubstituted alkenes are easy to synthesize from readily available starting materials by catalytic cross-coupling.

*E*- and *Z-*trisubstituted alkenyl chlorides {#S3}
=============================================

We prepared *E*-**6** ([Fig. 2a](#F2){ref-type="fig"})^[@R29]^ by hydroboration of styrene and cross-coupling of the resulting alkylborane with commercially available *E*-2-bromo-2-butene (*E*-**7**; 85% yield, \>98% *E*). Subjection of *E*-**6** and *E*-**2** (used without purification) to 1.0 mol% **Mo-2** afforded *E*-**3a** in 81% yield (\>98% conv.) and 95:5 *E:Z* selectivity after just four hours (compared to 65% yield and 70:30 *E:Z*, 10 mol% **Mo-2**, 12 h); reaction with *Z*-**2** led to similar stereoselectivity but yield was lower (50%). Cross-coupling of arylboronic acid **8**, which is purchasable, and *E*-**7** delivered *E*-**9** in 81% yield (\>98% *E*); ensuing cross-metathesis with 3.0 mol% **Mo-1** and *Z***-2** afforded *E*-**3b** in 90% yield and \>98% stereoretention after four hours (compared to 30% yield, 10 mol% **Mo-1**, 12 h).

*E*-Trisubstituted alkenyl chlorides **3c**-**h** ([Fig. 2a](#F2){ref-type="fig"}) were isolated in 56--91% yield and 93:7 to \>98:2 *E:Z* selectivity. The trialkylaluminum reagents necessary for zirconocene-catalyzed carbometallation approach are not compatible with an epoxide^[@R30]^ (see **3c**; lower yield due to difficult purification), a carboxylic ester (see **3e**), a B(pin) (pin, pinacolato) group (see **3f**) or a Boc-protected (Boc, *tert*-butoxycarbonyl) indole moiety^[@R31]^ (see **3h**). Reactions leading to dienes **3e**-**f** were chemoselective, as cross-metathesis involving the electron deficient but less substituted enoate or alkenyl--B(pin) groups is less favored. Compounds **3b** and **3g**-**h** were secured in \>85% yield and as a single stereoisomer, although higher catalyst loading was needed for the last product. Cross-metathesis with aryl alkenes is often particularly difficult.

*Z*-Trisubstituted alkenyl halides were synthesized by incorporating a minor procedural change ([Fig. 2b](#F2){ref-type="fig"}). With commercially available *Z*-**7**, by an otherwise identical sequence as before, we prepared *Z*-**6** in 75% yield as a single stereoisomer (\>98% *Z*). Cross-metathesis with *Z*-**2** and 3.0 mol% **Mo-2** afforded *Z*-**3a** in 86% yield and 91:9 *Z:E* ratio after four hours. Additional examples are provided in [Fig. 2b](#F2){ref-type="fig"} (**3i**-**m**). Halogenated allyl--B(pin) compound **3k**, amenable to catalytic diastereo- and enantioselective additions to electrophiles, was prepared in 83% yield and 95:5 *Z:E* ratio. Preparation of **3l** (89% yield, 86:14 *Z:E*) shows that a Lewis basic trialkylamine is tolerated. Reactions with aryl alkenes were efficient but less stereoselective than the related *E*-selective processes \[e.g., *Z*-**3b**, 65% yield (pure *Z* isomer), 79:21 *Z:E*\]. *Z*-trisubstituted alkenes cannot be accessed by carboalumination without a properly situated directing group^[@R13],[@R15]^.

Transformations affording *E*-alkenyl chlorides ([Fig. 2a](#F2){ref-type="fig"}) are generally more stereoretentive compared to those furnishing *Z* isomers ([Fig. 2b](#F2){ref-type="fig"}). This can be accounted for based on repulsive interactions within the metallacycle intermediates. For processes affording *E* alkenes ([Fig. 2c](#F2){ref-type="fig"}, left panel), the intermediacy of **I** is likely favored because of the steric pressure in **II**, caused by the proximity of the methyl group oriented towards the sizeable aryloxide ligand (Cα substituents are nearer to the sizeable ligand compared to those at Cβ^[@R28]^). There is also the propinquity of the larger alkenyl group (R~L~) and the adjacent chloride substituent (vs. R~S~ and Cl in **I**). With processes affording *Z* isomers ([Fig. 2c](#F2){ref-type="fig"}, right panel), the energy gap between **III** and **IV** is probably smaller, because now it is within the metallacycle leading to the *Z* alkene (**III**) that R~L~ and the chlorine atom are oriented in the same direction. Therefore, *Z:E* ratios are lower for reactions with a larger group at the fully substituted carbon of the alkene (e.g., aryl group in **3b**), as there is more steric pressure in **III** with a phenyl group as the larger Cβ substituent (R~L~). Similarly, *Z*-**3k** is generated with greater stereoretention (95% compared to ≤91% *Z*) because the substrate, accessed by a phosphine--Ni-catalyzed diene hydroboration^[@R32]^, bears a larger *n*-Bu unit *cis* to the CH~2~B(pin) moiety (vs. Me); **IV** is destabilized further by a stronger repulsion between the Cα substituent and the aryloxide ligand (*n*-Bu instead of Me).

*E*- and *Z-*trisubstituted alkenyl bromides {#S4}
============================================

The pathway in [Fig. 1c](#F1){ref-type="fig"} and the formerly established electronic and steric factors,^[@R28],[@R33]^ imply that with a dihaloalkene containing two different halogen atoms \[e.g., *Z*-1-bromo-2-fluoroethene (*Z*-**10**), [Fig. 3a](#F3){ref-type="fig"}\], the metallacyclobutane (cf. **A**, Cycle 1, [Fig. 3a](#F3){ref-type="fig"}) generating alkylidene **iii**′ and an alkenyl fluoride should be favored. Indeed, treatment of **Mo-1** or **Mo-2** with *Z*-**10** afforded alkenyl fluoride **11** (based on ^1^H NMR analysis). The ensuing transformation via alkylidene **iii**′ and metallacyclobutane **vii**′ (Cycle 1, [Fig. 3a](#F3){ref-type="fig"}) would then give the alkenyl bromide product. This is unlike the reactions with mono- or 1,2-disubstituted alkenes, which involve bromo-substituted alkylidenes and produce fluoro-substituted alkenes^[@R33]^.

In practice ([Fig. 3b](#F3){ref-type="fig"}, left panel), with 1.0 mol% **Mo-2**, cross-metathesis between *Z*-**10** and *E*-**6** led to the formation of trisubstituted alkenyl bromide *E*-**12a** in 95:5 bromo:fluoro selectivity, 90% yield (pure bromide) and with complete retention of stereochemistry (\>98% *E*). The transformation involving *Z*-**10** and *Z*-**6** generated *Z*-**12a** in 66% yield (pure bromide) and 95% stereoisomeric purity. Akin to reactions of alkenyl chlorides ([Fig. 2](#F2){ref-type="fig"}), when 1,1-disubstituted alkene **1a** was used (instead of *Z*- or *E*-**6**; [Fig. 3b](#F3){ref-type="fig"}), **12a** was formed with much lower stereoselectivity (70:30 *E:Z*). Additional cases are shown in [Fig. 3c](#F3){ref-type="fig"} (**12b**-**f**), including **12f**, which contain acetal groups, which are problematic with trialkylaluminum compounds^[@R34]^.

The preference for the bromo-alkenyl product is higher for the *E* isomers (92:8--97:3 compared to 83:17--89:11 bromo:fluoro, respectively). This might be because for *Z* alkene substrates, steric repulsion between the alkyl group and Br in the more favorable **ix** renders formation of the alternative metallacycle **x** to be more competitive (Cycle 3, [Fig. 3a](#F3){ref-type="fig"}). Collapse of **x** would generate disubstituted alkylidene **ii** ([Fig. 1b](#F1){ref-type="fig"}), which can then react with *Z*-**10** with the expected sense of selectivity (see **A**, Cycle 1, [Fig. 3a](#F3){ref-type="fig"}) to give more of the alkenyl fluoride byproduct. Reactions with 1,2-dibromoethene were considerably less efficient.

Other types of *E*- or *Z*-trisubstituted alkenes {#S5}
=================================================

Trisubstituted alkenes with a longer chain alkyl unit (instead of a methyl group) may be prepared ([Fig. 4a](#F4){ref-type="fig"}). Hydroboration^[@R35]^ of 4-octyne followed by catalytic cross-coupling^[@R36]^ afforded **13** in 82% overall yield (\>98% *E*). Subsequent catalytic cross-metathesis generated chloride **14** in 92% yield and 82:18 *E:Z* selectivity; bromide **15** was obtained in 92:8 bromo:fluoro selectivity, 80% yield (pure bromide) and the same stereoisomeric purity. The diminished stereoretention probably originates from the smaller size difference between the alkyl groups (i.e., *n*-Pr and (CH~2~)~4~Ph) positioned at Cβ of the corresponding metallacyclobutanes. This strategy is attractive especially when the use of higher order not-as-readily-available trialkylaluminum reagents would be a less desirable option (compared to Me~3~Al)^[@R15]^.

Non-halogenated trisubstituted alkenes may be prepared efficiently and stereoselectively ([Fig. 4b--c](#F4){ref-type="fig"}). Treatment of *E*-**6** with a 61:39 *E:Z* mixture of 1,2- disubstituted homoallylic ether **16** and 5.0 mol% **Mo-3** led to the formation of *E*-**17** in 52% yield and 93:7 *E:Z* ratio ([Fig. 4b](#F4){ref-type="fig"}). Similarly, *E*-**18** was obtained in 69% yield as a single stereoisomer (\>98% *E*). Because of the more sizeable reaction partners (vs. a *Z*-1,2-dihaloethene), use of a less sterically congested complex with mesityl-substituted (mesityl, 2,4,6-trimethylphenyl) aryloxide ligand led to higher efficiency (i.e., **Mo-3** instead of **Mo-2**). Since the catalyst can react with either 1,2-disubstituted alkene isomer to generate the same alkylidene, this starting material need not be stereoisomerically pure; cross-metathesis between a 1,1-disubstituted and an *E*- or *Z*-1,2-disubstituted alkene can lead to stereoisomeric mixtures (see [Fig. 1b--c](#F1){ref-type="fig"}).

*Z*-Trisubstituted alkenes (*Z*-**18** and *Z*-**20**, [Fig. 4c](#F4){ref-type="fig"}) were accessed likewise. Because these transformations proceed via more congested metallacycles (see **III**-**IV** vs. **I**-**II**, [Fig. 2c](#F2){ref-type="fig"}), use of monoaryloxide chloride species **Mo-4**^[@R37]^ led to improved efficiency; for example, *Z*-**18** was isolated in 28% yield when pyrrolide complex **Mo-3** was used (compared to 64% yield). Mo chloride complexes are ineffective in promoting reactions that afford alkenyl halides, as decomposition of the purported chloro- or bromo-substituted metallacyclobutanes is probably facile^[@R37]^. The present approach complements a recent study regarding stereoselective synthesis of trisubstituted alkenes starting from carboxylic acids and involving alkenylzinc reagents, which are often derived from alkenyl halide precursors^[@R38]^.

Synthesis of biologically active compounds {#S6}
==========================================

The first application pertains to stereoselective synthesis of naturally occurring anti-fungal agent indiacen B^[@R31],[@R39],[@R40]^ ([Fig. 5a](#F5){ref-type="fig"}). Diene *E*-**3f** was prepared from enal **21** and bis\[(pinacolato)boryl\]methane (both are commercially available) via **22** in two steps^[@R41]^, including a chemoselective and stereoretentive cross-metathesis, in 91% yield and 96% *E:Z* ratio. Indiacen B was obtained after an additional catalytic step in 65% yield. The three-step route, affording the target molecule in 54% overall yield, compares favorably to a previously reported seven-step synthesis^[@R31]^, which involved zirconocene-catalyzed methyl-aluminum addition to an alkyne, generating the final product in 16% overall yield.

Preparation of anti-leishmanial and anti-inflammatory compound coibacin D^[@R42]^ highlights a series of five catalytic processes ([Fig. 5b](#F5){ref-type="fig"}). Stereoisomerically pure *E*,*E*-diene **25** was accessed in 72% yield by a two-step procedure involving hydroboration of 2-butyne and cross-coupling of the resulting alkenylboronic acid with allylic alcohol **24**^[@R43]^. Compound *E*-**3n** was then obtained via *E*-alkenyl--B(pin) intermediate **26** through two chemo-selective and stereoretentive cross-metathesis reactions. The first was the conversion of **25** to **26** by a transformation involving 3.0 mol% **Mo-3** and vinyl--B(pin); use of the slightly more hindered complex **Mo-3** (instead of **Mo-1**) allowed for exceptional stereocontrol (see [Extended Data Fig. 2](#F7){ref-type="fig"} for details), and the less hindered aryl alkene underwent reaction exclusively. A second cross-metathesis was performed with 3.0 mol% **Mo-2** and 1,2-dichloroethene *Z*-**2** (5.0 equiv.), delivering *E*-**3n** in 59% yield and 97:3 *E:Z* selectivity; in this case, despite being more hindered, it was the trisubstituted alkene that reacted preferentially. Homoallylic alcohol **28** was accessed in 76% yield after another efficient and chemoselective cross-coupling between *E*-**3n** and **27**. This was followed by a third kinetically controlled chemoselective cross-metathesis with **28**, *Z*-2-butene-1-4,diol and catechothiolate complex **Ru-1**^[@R44],[@R45]^. The resulting *Z*-allylic alcohol, generated in 94:6 *Z:E* selectivity was transformed to racemic coibacin D in 57% overall yield (\>98:2 *E*,*E* at the acyclic alkene sites). Coibacin D was accordingly obtained in seven steps (longest linear sequence), 12% overall yield, and as a single alkene isomer, comparing favorably with the previously reported 4% overall yield after six steps to give racemic coibacin D as a 75:25 mixture of alkene isomers^[@R46]^. Moreover, alkenyl chloride *E*-**3n** was converted to dienoate **29** (70% yield, \>98% *E*), a compound applicable to synthesis of anti-tumor agent kimbeamide A^[@R47]^. The requisite amine fragment has been prepared through kinetically *E*-selective cross-metathesis^[@R28]^.

Alkenyl chlorides can be ineffective in cross-coupling and, in such cases, the corresponding bromo-alkene is needed. One instance relates to stereoselective preparation of enyne **31** ([Fig. 5c](#F5){ref-type="fig"}), a compound used to prepare immunosuppressant and anti-cancer^[@R48]^ natural product pateamine A^[@R49]^. Conversion of *E*-**7** to homoallylic silyl ether **30** involved enantiomerically pure and commercially available *S*-propylene oxide, and was accomplished in two straightforward steps. Cross-metathesis between **30** and *Z*-1-bromo-2-fluoroethene (*Z*-**10**; 3.0 equiv.) with 5.0 mol% **Mo-5** afforded *E*-**12g** in 88:12 bromide:fluoride selectivity and as a single alkenyl bromide isomer. A catalyst with a smaller aryloxide ligand was needed for higher efficiency because a metallacyclobutane with a larger Cβ substituent must be accommodated (for example, 63% conv. to *E*-**12g** with **Mo-2** under otherwise identical conditions). Cross-metathesis was again followed by cross-coupling, this time between *E*-**12g** and 3,3-diethoxy-1-propyne (commercially available). Cross-coupling with the related alkenyl chloride was ineffective (\<2%). Unmasking of the diethyl acetal group afforded **31** (41% overall yield for three steps). The fragment was thus synthesized by a shorter route (five compared to eight steps) and in similar yield (34% compared to 33% overall yield reported previously^[@R48]^).

Conclusions {#S7}
===========

We demonstrate that there are two crucial factors for successful development of kinetically controlled stereoretentive cross-metathesis reactions that afford trisubstituted alkenes. A variety of trisubstituted alkene substrates must be readily accessible in stereoisomerically pure form, and a set of catalysts that can catalyze reactions between tri- and 1,2-disubstituted alkenes efficiently and stereoselectively must be available. Accordingly, we show that a sequence beginning with cross-coupling between *E*- or *Z*-trisubstituted 2-bromo-2-butene and an organoboron compound and then a stereoretentive cross-metathesis with an appropriate Mo-based complex furnishes *E*- or *Z*-trisubstituted alkenes efficiently and in high stereoisomeric purity. The approach, which merges cross-coupling with cross-metathesis, underlines a key difference between two major classes of catalytic processes. Substrates in cross-coupling are more distinct and chemoselectivity is less of a problem, offering facile access to the necessary trisubstituted alkene substrates. Cross-metathesis can then be used to access a wider range of alkenes readily and in high stereoisomeric purity. The relationship between cross-coupling and cross-metathesis has another dimension: the *E*- or *Z*-trisubstituted alkenyl halides may be converted to other trisubstituted alkenes with little or no loss of stereochemical purity through another cross-coupling.

By adopting the proper combination of these two important catalytic C--C bond forming transformations, we have been able to address a critical unresolved problem in chemical synthesis. The present study further highlights the attributes of stereogenic-at-Mo complexes as effective alkene metathesis catalysts, which further benefit from the possibility of using them as commercially available paraffin tablets^[@R50]^.

Extended Data {#S8}
=============

![Nonproductive olefin metathesis pathways\
Cross-metathesis between **v** and **1a** via symmetrical metallacyclobutane **iv**′ (pathway on the right, in black) is more likely than one entailing the intermediacy of complex **iv**″ (pathway on the left, in red). This is as a result of greater steric pressure between the Ca substituent and the sizeable aryloxide ligand \[see: Nguyen, T. T., Koh, M. J., Shen, X., Romiti, F., Schrock, R. R. & Hoveyda, A. H. *Science* **352**, 569--575 (2016)\]. Cycloreversion of **iv**′ would then re-generate **v** and afford **1a** (nonproductive process).](nihms917306f6){#F6}

![Distinctive pathways for cross-metathesis of 22 and vinyl--B(pin) with Mo-1,2\
**a.** Cross-metathesis between **25** and vinyl--B(pin) in the presence of **Mo1** and **Mo-2** results in different product distribution and stereoselectivity profiles. **b,** The reactions proceed via **mcbI~Me~** because of severe steric repulsion between the larger Cb aryl group in **mcbII~Me~** and the Me units of the aryloxide ligand in **Mo-3**. Byproduct **33** may react with vinyl-B(pin) to furnish *Z*-**32. c,** There is less steric pressure at Cβ in **mcbI*~t-~*~Bu~** and **mcbII*~t-~*~Bu~**; consequently, steric repulsion between the Cα metallacyclobutane substituent and an *ortho* fluorine substituent of the arylimido becomes more of a factor. Thus, cross-metathesis probably proceeds via **mcbII*~t-~*~Bu~** to afford the corresponding alkenyl--B(pin) compound (*E*-**32**). Ensuing reaction of **xiv** with vinyl--B(pin) likely affords **34**, which may then react with vinyl--B(pin) to furnish *E*-**3n**.](nihms917306f7){#F7}
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![The challenge of developing stereoselective trisubstituted alkene cross-metathesis\
**a**, Reaction between 1,1-disubstituted alkene **1a** and *Z*-**2** required 10 mol% loading for ≥72% conversion in 12 hours, affording *E*-**3a** in ≤80:20 *E:Z* ratio. Formation of *E*-**3b** was sluggish but more stereoselective due to substrate control. **b**, Inefficiency and low stereoselectivity is probably low stability of methylidene **v** and minimal size difference between the substituents in **1a. c**, With a trisubstituted alkene (*E*-**6**), catalysis is initiated by reaction with *Z*-**2** to generate **iii**, which is more robust than a methylidene complex. Moreover, the intermediacy of metallacyclobutane **vii** (vs. **iv**), should lead to superior stereoselectivity. Conv. and isomeric ratios determined by analysis of ^1^H NMR spectra of unpurified mixtures; yields are for isolated and purified products. See the [Supplementary Information](#SD1){ref-type="supplementary-material"} for details.](nihms917306f1){#F1}

![Synthesis of *Z*- and *E*-Trisubstituted alkenyl chlorides\
**a**, *E*-Trisubstituted alkene substrates can be accessed by hydroboration of a monosubstituted alkene followed by cross-coupling with *E*-**7**. Subsequent cross-metathesis with *Z*- or *E*-**2** was highly efficient, affording products in exceptional isomeric purity. Synthesis of *E*-**3b** shows an alternative way of merging cross-coupling and cross-metathesis. The approach is broadly applicable. **b**, *Z*-trisubstituted alkenyl chlorides may be accessed efficiently. **c**, Differences in steric pressure in metallacyclobutanes leading to *E*- and *Z*-trisubstituted alkene products provides an explanation for why transformations leading to the latter isomers are less selective: the energy difference between **I** and **II** (leading to *E* isomers) is larger than that separating **III** and **IV** (to give *Z* isomers). Conv. and isomeric ratios determined by analysis of ^1^H NMR spectra of unpurfied mixtures; yields are for isolated and purified products. See the [Supplementary Information](#SD1){ref-type="supplementary-material"} for details. Boc, *tert*-butoxycarbonyl; Fc, ferrocenyl; pin, pinacolato; Bn, benzyl; R~L~, larger substituent; R~S~, smaller substituent, PMB, *para*-methoxybenzyl; dppf, 1,1′-bis(diphenylphosphino)ferrocene.](nihms917306f2){#F2}

![Synthesis of *Z*- and *E*-trisubstituted alkenyl bromides\
**a**, Attributes of a Mo alkylidene dictate that reaction with *Z*-**10** preferentially generates a bromo-substituted alkylidene and an alkenyl fluoride byproduct (e.g., **11**) via **A**. The subsequent steps should afford *E*- or *Z*-trisubstituted alkenyl bromides (Cycles 2 and 3, respectively). **b**, Reaction between *Z*-**10** and *E*-**6** afforded *E*-**12a** in 90% yield, 95:5 Br:F ratio, and \>98:2 *E:Z* selectivity; with *Z*-**6**, *Z*-**12a** was obtained in 66% yield, 83:17 Br:F ratio, and 5:95 *E:Z* selectivity. The difference in bromo:fluoro selectivity probably originates from the increased steric pressure in metallacyclobutane **ix** (Cycle 3, Fig. 3a), leading to intermediacy of **x** and alkenyl fluoride byproduct (via **ii**, [Fig. 1](#F1){ref-type="fig"}). When **1a** was used, **12a** was generated with lower efficiency and stereoselectivity. **c**, The method has considerable scope and may be used with substrates containing acetals. Conv. and isomeric ratios determined by analysis of ^1^H NMR spectra of unpurified mixtures; yields are for isolated and purified products. See the [Supplementary Information](#SD1){ref-type="supplementary-material"} for details. Bn = benzyl; pin = pinacolato; PMP = *para-*methoxyphenyl.](nihms917306f3){#F3}

![Synthesis of *E*- or *Z*-trisubstituted non-halogenated alkenes\
**a,** Trisubstituted alkenes with substituents other than a methyl group can be prepared efficiently and stereoselectively. **b**, The present strategies may be utilized to synthesize non-halogenated alkenes. An isomeric mixture of 1,2-disubstituted alkenes may be used, and sterically less hindered **Mo-3** (vs. **Mo-2**) allowed for higher efficiency to be attained. **c,** *Z*-Trisubstituted alkenes may be obtained in a similar manner (e.g., *Z*-**6**); as with the alkenyl halides, reactions are less stereoretentive than when *E* isomers are generated. For higher yield in these instances, involving especially hindered metallacyclobutanes, a Mo chloride complex is needed. Conv. and isomeric ratios determined by analysis of ^1^H NMR spectra of unpurified mixtures; yields are for isolated and purified products. See the [Supplementary Information](#SD1){ref-type="supplementary-material"} for details. TBS, *tert*-butyldimethylsilyl; PMB, *para*-methoxybenzyl; Mes, 2,4,6-trimethylphenyl.](nihms917306f4){#F4}

![Synthesis of biologically active compounds\
**a**, Indiacen B (anti-fungal) was synthesized stereoselectively in 54% overall yield in three steps. **b**, For synthesis of coibacin D (anti-inflammatory), diene **25**, prepared by catalytic cross-coupling, was transformed to the desired target by a sequence of four catalytic processes: two chemo- and stereoselective cross-metathesis to give *E*-**3n** via **26**, a cross-coupling reaction to afford **28** and a Ru-dithiolate catalyzed cross-metathesis. Dienoate **29**, which may be used to prepare kimbeamide A (anti-tumor). **c,** Cross-metathesis of homoallylic silyl ether **30**, synthesized in 83% yield from *E*-**7**, afforded *E*-**12g** in 88:12 bromo:fluoro ratio. Subsequent cross-coupling afforded **31**, a fragment used in a total synthesis of pateamine A (immunosuppressant). Conv. and isomeric ratios determined by analysis of ^1^H NMR spectra of unpurified mixtures; yields are for isolated and purified products. See the [Supplementary Information](#SD1){ref-type="supplementary-material"} for details. pin, pinacolato; DME, dimethoxyethane; TEMPO, 3,3,5,5-tetramethyl-1-pyrroline-1-oxide; Mes, 2,4,6-trimethylphenyl; dpephos, bis\[(2-diphenylphosphino)phenyl\]ether; TBSOTf, *tert*-butyldimethylsilyl triflate; DABCO, 1,4-diazabicyclo\[2.2.2\]octane; LiTMP, lithium 2,2,6,6-tetramethylpiperidide.](nihms917306f5){#F5}

[^1]: These authors contributed equally.
